Champions for Bioscience

Tuesday, October 31, 2017


Four Companies Win Their Share of $150,000 in Healthcare Shark-Tank Event

Thursday, October 26, 2017

During the 2017 Prime Health Challenge, six healthcare technology startups pitched to representatives from 16 host institutions, including Kaiser Permanente, Metro Community Provider Network, AllHealth Network, Centura, UCHealth, and SCL Health. Over 500 audience members watched as each company competed for an opportunity to prove their solutions with Colorado healthcare institutions.

Early this summer, companies from around the country submitted applications to compete in the Prime Health Challenge. Over the past 3-months, experts from across the industry evaluated the proposals through the Prime Health Qualify process and narrowed the list down to six finalists. Thanks to funding from The Colorado Health Foundation, winners were rewarded with a share of the $150,000 prize.

“The Colorado Health Foundation is excited about its continued partnership with Prime Health in order to support the intersection of health care, innovation and low income communities across Colorado” said Ben Bynum, M.D., Portfolio Director of Private Sector Engagement at The Colorado Health Foundation.

Steve Adams, CEO of Prime Health, explained, “The healthcare industry presents unique challenges for entrepreneurs. Collaborating with providers and patients early on is key to success and for the winners of tonight’s Challenge, this experience will provide invaluable knowledge on how to scale innovation in the healthcare industry.”

Nymbl receives their award.

The first place award of $45,000 went to Nymbl Science, who has developed a comprehensive system for measuring, tracking, and improving balance for patients at-risk of falls.

“It was a dream come true for Nymbl to get pilot offers from four of the largest healthcare providers in the state of Colorado, and we are honored to receive the prize money to help make these pilots a reality. We are extremely thankful for the opportunity to pitch and for the sponsors of Prime Health. It was humbling to be on stage with so many other terrific companies, each talented enough to win, and all of which will impact healthcare in significant ways,” said Edward Likovich, Vice President of Operations at Nymbl.

AI Health, which has created a platform to improve communication between hospitals and post-acute care settings, such as, nursing homes, skilled nursing facility, home health, and rehab facilities, won the Safety Net Award. This award of $45,000 was specifically designated for a startup that addressed pain points for underserved populations.

As Dr. Kenneth Bellian, Co-Founder of AI Health, described, "We are very thankful to Prime Health, Colorado Health Foundation and all the participating host institutions for putting together such a wonderful program. We are very excited to have won the Safety Net Award because we know that we can help patients of any background find the best post-acute care facilities based on their specific situation. This results in better outcomes for the patient and lower costs for the payer. This is especially important for patients that are at risk, underfunded, and/or unfunded."

The second place award of $35,000 went to Redox, a Wisconsin-based startup who provides health systems with a platform that acts as a single access point for all cloud-based applications, providing access controls and monitoring while eliminating integrations. Through this, the company hopes to empower innovation and ease the burden of EHR interoperability.

The Third Place of $25,000 went to Listen.MD, an artificial intelligence based scribing application that allows providers to focus on personal interactions with patients.

While only the top four companies won a share of the prize money, all six finalists received bids to pilot their solutions at a host institution. For more information on these companies, and to stay up to date on all the trends in Colorado digital health innovation, visit

Continue Reading

‘It’s All About the Kids’

Tuesday, October 24, 2017


DMC Biotechnologies, Inc. Awarded Competitive Grant from the U.S. Department of Agriculture National Institute of Food and Agriculture

Friday, October 20, 2017

DMC Biotechnologies, Inc. (, an early-stage biotechnology company,has been awardeda U.S. Department of Agriculture National Institute of Food and Agriculture (USDA NIFA) Small Business Innovation Research (SBIR)Phase Igrantfor $100,000 to commercialize their proprietary high throughput metabolic engineering platform that enables the rapid development of microbial hosts for the production of a broad diversity of bio-based products.

The USDA SBIR program is a highly competitive program which seeks to transform early-stage scientific discovery into societal and economic benefit by catalyzing private sector commercialization of technological innovations.

Biology is fundamentally a manufacturing language with massive potential to positively impact our world. Increased deployment of bio-based products can reduce our dependence on foreign oil, improve the nutrition of the foods that we eat, provide domestic manufacturing of existing products, and enable new-to-the world materials that are only accessible using the precision of biology. DMC makes bio-based products using enhanced microbial fermentation. We are building a capital-efficient, multi-product company using our patent-pending technology that overcomes key barriers that have historically impeded efforts in this sector.

“For small agricultural businesses, the federal government is a key, initial investor to help them get great ideas into the marketplace,” said NIFA Director, Sonny Ramaswamy. “The feasibility and scalability of these business concepts are evaluated through our peer review process, and businesses get to keep their intellectual property rights as they commercialize their ventures.”

“The vision for DMC is to develop bio-based processes that are superior in cost and quality to existing manufacturing routes. We are pleased to be recognized with this highly competitive award from the USDA and are grateful for their support of our mission.This SBIR grant plays a vital role in advancing our technology along the commercial path,” said Matt Lipscomb, Ph.D., CEO and Co-Founder of DMC.

The Small Business Innovation Research Program (SBIR) is coordinated by the Small Business Administration and administered by 11 federal agencies, including USDA. It encourages domestic small businesses to engage in high-growth research and development with high potential for commercialization and that could lead to significant public benefit. Phase I grants invest in feasibility and proof of concept studies. Phase II grants help successful Phase I projects scale up, implement, and commercialize their ventures. Topic areas include forests and related resources; plant production and protection – biology; animal production and protection; air, water, and soils; food science and nutrition; rural and community development; aquaculture; biofuels and biobased products; small and mid-size farms; and plant production and protection – engineering.

To learn more about the USDA SBIR/STTR program, visit:

Continue Reading

Diversity Suits the C-Suite

Wednesday, October 18, 2017


Collaborative by Nature

Tuesday, October 10, 2017


Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summits PhaseOut DMD Clinical Trial

Thursday, October 05, 2017

CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society

Continue Reading

MBC Pharma Inc. Awarded a SBIR Phase II Grant to Further Develop a Novel Bone-Targeted Combination Treatment for Osteosarcoma

Thursday, October 05, 2017

MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $2M Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to build upon the success of the Phase I grant—demonstration of in vivo efficacy in model systems of osteosarcoma. The new work will focus on optimizing the method of use and testing the drug combination in spontaneous canine osteosarcoma.  

Smart, Hard-Working and Happy

Monday, October 02, 2017